SCHEMBL5658380

SCHEMBL5658380

COc1ccc2cc3c(cc2c1)Oc1ccccc1CC3=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 3/20 0.43
HPGD P15428 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
GAA P10253 2/20 0.43
ALOX12 P18054 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP2A6 P11509 2/20 0.41
PPIB P23284 1/20 0.41
ABCB1 P08183 1/20 0.41
AR P10275 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
CYP1A2 P05177 1/20 0.41
MAOB P27338 2/20 0.40
ACHE P22303 2/20 0.40
MAOA P21397 1/20 0.40
MAPK1 P28482 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5658535 0.85 MAOA (0.52) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL7108704 0.80 MAOA (0.46) KDM4EALDH1A1MAPTHPGDMAOB
SCHEMBL7172150 0.79 MAOB (0.48) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL8377614 0.79 NPC1 (0.53) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL26882761 0.75 GSTP1 (0.55) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL7511173 0.74 MAOA (0.59) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL5757673 0.74 MAOA (0.59) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL5251983 0.72 CYP2A6 (0.56) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL7112833 0.72 MAOA (0.50) RAB9AKDM4EALDH1A1MAPTHPGD
SCHEMBL7115046 0.71 ABCG2 (0.52) KDM4EALDH1A1HPGDABCG2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262309-B2 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof GLAXOSMITH KLINE ISTRAZIVOCKI CENTAR ZAGREB, D.O.O. (HR) 2007-08-28 US disclosed
EP-1492795-B1 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF PLIVA ISTRAZIVACKI INST D O O (HR) 2005-11-16 EP disclosed
US-20050130964-A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130964-A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof TNF, IL1A, IL1B NPC1 3314/4885RAB9A 3608/4885KDM4E 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.